Spasticity: number of participants reporting reduction of 30% in the spasticity NRS ( · health problem or population
Summary of findings table ‐ Cannabis probably leads to higher spasticity: number of participants reporting reduction of 30% in the… compared with placebo (moderate certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · health problem or population
It is very uncertain whether summary of findings table ‐ Cannabis changes pain:number of participants reporting pain relief of 50% or greater… compared with placebo (very low certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · health problem or population
Summary of findings table ‐ Cannabis probably leads to higher PGIC:number of participants reporting much or very much improvement… compared with placebo (moderate certainty).
1 finding from 1 review
Health‐related quality of life. Mean change from baseline · health problem or population
1 finding from 1 review
Number withdrawn due to adverse events · health problem or population
Summary of findings table ‐ Cannabis may leads to higher withdrawn due to adverse events ( compared with placebo (low certainty).
1 finding from 1 review
SAEs · health problem or population
Summary of findings table ‐ Cannabis showed no clear difference in SAEs: number of participants with SAEs ( compared with placebo (low certainty).
1 finding from 1 review
Specific adverse events:nervous system disorder · health problem or population
Summary of findings table ‐ Cannabis may leads to higher specific AEs:number of participants reporting nervous system… compared with placebo (low certainty).
1 finding from 1 review
Adverse events: psychological disorders · health problem or population
Summary of findings table ‐ Cannabis may leads to higher specific AEs: number of participants reporting psychiatric disorders ( compared with placebo (low certainty).
1 finding from 1 review
Specific AEs: number of participants reporting drug tolerance ( · health problem or population
It is very uncertain whether summary of findings table ‐ Cannabis changes specific AEs: number of participants reporting drug tolerance ( compared with placebo (very low certainty).
1 finding from 1 review
Absence of nausea ( · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoid plus other anti‐emetic agent changes absence of nausea ( compared with other anti‐emetic monotherapy (very low certainty).
1 finding from 1 review
Absence of vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of vomiting ( compared with other anti‐emetic monotherapy (low certainty).
1 finding from 1 review
Absence of nausea and vomiting ( · people with chemotherapy‐induced nausea and vomiting
Cannabinoid plus other anti‐emetic agent showed no clear difference in absence of nausea and vomiting ( compared with other anti‐emetic monotherapy (low certainty).
1 finding from 1 review
Withdrawal for any reason (medium term: treatment duration from 5 to 8 weeks) · people with chemotherapy‐induced nausea and vomiting
Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal any reason ( compared with other anti‐emetic monotherapy (low certainty).
1 finding from 1 review
Withdrawals due to adverse events · people with chemotherapy‐induced nausea and vomiting
It is very uncertain whether cannabinoid plus other anti‐emetic agent changes withdrawal due to adverse event ( compared with other anti‐emetic monotherapy (very low certainty).
1 finding from 1 review
Lack of efficacy withdrawal · people with chemotherapy‐induced nausea and vomiting
Cannabinoid plus other anti‐emetic agent showed no clear difference in withdrawal due to lack of efficacy ( compared with other anti‐emetic monotherapy (low certainty).
1 finding from 1 review